Last reviewed · How we verify
BLU-5937
BLU-5937 is a P2X3 receptor antagonist Small molecule drug developed by Bellus Health Inc. - a GSK company. It is currently in Phase 3 development for Chronic cough, Refractory chronic cough. Also known as: Camlipixant.
BLU-5937 is a selective P2X3 receptor antagonist that blocks pain signaling in sensory neurons.
BLU-5937 is a small molecule that acts as a P2X purinoceptor 3 antagonist. It is being studied in clinical trials for various conditions, including chronic refractory cough, chronic pruritus, atopic dermatitis, refractory chronic cough, and cough.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
CNS / neurology attrition
-3.0pp
CNS drugs have historically high Phase 3 failure rates (notably in Alzheimer disease + major depression). -
Big-pharma sponsor
+3.0pp
Bellus Health Inc. - a GSK company is a top-20 pharma sponsor — historical approval rates run ~3pp above average due to scale, regulatory experience, and trial-design quality.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | BLU-5937 |
|---|---|
| Also known as | Camlipixant |
| Sponsor | Bellus Health Inc. - a GSK company |
| Drug class | P2X3 receptor antagonist |
| Target | P2X3 |
| Modality | Small molecule |
| Therapeutic area | Pain Management / Neurology |
| Phase | Phase 3 |
Mechanism of action
P2X3 receptors are ion channels expressed on nociceptive (pain-sensing) neurons that mediate acute and chronic pain signals. By antagonizing P2X3, BLU-5937 reduces the transmission of pain signals from peripheral nerves to the central nervous system. This mechanism is particularly relevant for conditions involving visceral and neuropathic pain.
Approved indications
- Chronic cough
- Refractory chronic cough
Common side effects
- Taste disturbance
- Dizziness
- Headache
- Nausea
Key clinical trials
- A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough (PHASE3)
- A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough (PHASE3)
- Assessment of the Pharmacokinetics of BLU-5937 Extended Release Prototypes and a BLU-5937 Immediate Release Reference Formulation (PHASE1)
- Evaluation of the Potential Drug-drug Interactions Between Gemfibrozil or Dabigatran Etexilate and Camlipixant (PHASE1)
- Evaluation of the Effect of Rifampin and Rabeprazole on the Pharmacokinetics of Camlipixant (PHASE1)
- Evaluation of the Pharmacokinetics and Safety of BLU-5937 in Healthy Adult Japanese and Caucasian Subjects (PHASE1)
- A Multiple-Dose Study of BLU-5937 in Chronic Pruritus Associated With Atopic Dermatitis (PHASE2)
- Mass Balance Recovery, Absorption, Metabolism and Excretion of [14C]-BLU-5937 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BLU-5937 CI brief — competitive landscape report
- BLU-5937 updates RSS · CI watch RSS
- Bellus Health Inc. - a GSK company portfolio CI
Frequently asked questions about BLU-5937
What is BLU-5937?
How does BLU-5937 work?
What is BLU-5937 used for?
Who makes BLU-5937?
Is BLU-5937 also known as anything else?
What drug class is BLU-5937 in?
What development phase is BLU-5937 in?
What are the side effects of BLU-5937?
What does BLU-5937 target?
Related
- Drug class: All P2X3 receptor antagonist drugs
- Target: All drugs targeting P2X3
- Manufacturer: Bellus Health Inc. - a GSK company — full pipeline
- Therapeutic area: All drugs in Pain Management / Neurology
- Indication: Drugs for Chronic cough
- Indication: Drugs for Refractory chronic cough
- Also known as: Camlipixant
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing